Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;106(3):894-898.
doi: 10.3324/haematol.2020.252569.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Abhishek Maiti  1 , Caitlin R Rausch  2 , Jorge E Cortes  3 , Naveen Pemmaraju  3 , Naval G Daver  3 , Farhad Ravandi  3 , Guillermo Garcia-Manero  3 , Gautam Borthakur  3 , Kiran Naqvi  3 , Maro Ohanian  3 , Nicholas J Short  3 , Yesid Alvarado  3 , Tapan M Kadia  3 , Koichi Takahashi  3 , Musa Yilmaz  3 , Nitin Jain  3 , Steven Kornblau  3 , Guillermo Montalban Bravo  1 , Koji Sasaki  3 , Michael Andreeff  3 , Prithiviraj Bose  3 , Alessandra Ferrajoli  3 , Ghayas C Issa  3 , Elias J Jabbour  3 , Lucia Masarova  3 , Philip A Thompson  3 , Sa Wang  4 , Sergej Konoplev  4 , Sherry A Pierce  3 , Jing Ning  5 , Wei Qiao  5 , John S Welch  6 , Hagop M Kantarjian  3 , Courtney D DiNardo  3 , Marina Y Konopleva  3
Affiliations

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Abhishek Maiti et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival (OS). (A) Patients (pts) with relapsed or refractory (R/R) acute myeloid leukemia (AML) following front-line venetoclax (VEN) and hypomethylating agent (HMA) regimens, (B) according to receipt of salvage therapy; (C) patients receiving front-line HMA and VEN compared to front-line intensive chemotherapy in a population matched for age and European LeukemiaNet 2017 cytogenetic risk status; (D) patients with R/R disease after front-line HMA and VEN versus intensive chemotherapy. n: number; HR: hazard ratio; CI: confidence interval.
Figure 2.
Figure 2.
Landscape of mutations, salvage therapies, and responses in 41 patients with refractory disease or relapse after front-line venetoclax and hypomethylating agent (HMA). AML: acute myeloid leukemia; sAML: secondary AML; tAML: treatment-related AML; ELN: European LeukemiaNet; IC: intensive chemotherapy; NIC: non-intensive chemotherapy; CR: complete remission; CRi: incomplete hematologic recovery; MLFS: morphologica leukemia-free state.
See this image and copyright information in PMC

References

    1. Martin MG, Abboud CN. Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev. 2008;22(6):311-320. - PubMed
    1. Silva P, Neumann M, Schroeder MP, et al. . Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 2017;31(7):1640-1644. - PubMed
    1. Kantarjian H, Ravandi F, O’Brien S, et al. . Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422-4429. - PMC - PubMed
    1. DiNardo CD, Pratz K, Pullarkat V, et al. . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. - PMC - PubMed
    1. Maiti A, DiNardo CD, Rausch CR, et al. . Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II Trial. Blood. 2019;134(Suppl 1):2637.

Publication types

MeSH terms